In suspected ACS, hs-cTnI- vs. c-cTnI-guided care was associated with improved outcomes at 5 y in certain subgroups

Area of Science:

• Cardiology
• Clinical Diagnostics
• Biomarker Analysis

Background:

• High-sensitivity cardiac troponin assays allow for earlier detection of myocardial injury.
• Concerns exist regarding the potential for increased downstream testing and interventions with these sensitive assays.

Purpose of the Study:

• To evaluate the long-term safety and clinical outcomes associated with the implementation of a high-sensitivity cardiac troponin I assay.
• To assess the risk of myocardial infarction or death at five years following the introduction of the assay.

Main Methods:

• Observational analysis of a stepped-wedge, cluster randomized controlled trial (High-STEACS).
• Involved the implementation of a high-sensitivity troponin I assay across multiple healthcare facilities.
• Follow-up data collected over five years to assess patient outcomes.

Main Results:

• No significant increase in the risk of myocardial infarction or all-cause mortality was observed at five years.
• The implementation of the high-sensitivity assay did not lead to adverse clinical outcomes.
• This suggests the assay can be safely integrated into routine cardiac care.

Conclusions:

• The widespread adoption of high-sensitivity cardiac troponin I assays is supported by long-term safety data.
• These assays can be implemented without increasing the risk of major adverse cardiovascular events.
• Further research should focus on optimizing the use of these assays for improved patient management.